fda and glp 1 How Crackdowns Are Affecting GLP-1 Use In 2025 Compounded GLP-1 medications are trending

Treatment Options at Shed ShedRx offers a wide range of compounded GLP-1 treatments in different formats, making it more flexible than many other clinics

New patients have what they need to inject correctly

Food & Drug Administration (FDA-f)

Large cardiovascular outcome trials, including LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide), have demonstrated cardiovascular risk reduction with GLP-1 receptor agonists

( A Surge in Demand and a Regulatory Opening FDA regulations under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit pharmacies to compound drug products that are on the FDA shortage list

Lancet 2023;402:613-26